Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 11;114(4):592-599.
doi: 10.1093/jnci/djab221.

Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer

Edmund M Qiao  1   2 , Julie A Lynch  3 , Kyung M Lee  3 , Nikhil V Kotha  1   2 , Vinit Nalawade  1   2 , Rohith S Voora  1   2 , Alexander S Qian  2 , Tyler J Nelson  1   2 , Kosj Yamoah  4 , Isla P Garraway  5 , Tyler F Stewart  6 , J Kellogg Parsons  7 , Brent S Rose  1   2
Affiliations

Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer

Edmund M Qiao et al. J Natl Cancer Inst. .

Abstract

Background: Despite higher risks associated with prostate cancer, young African American men are poorly represented in prostate-specific antigen (PSA) trials, which limits proper evidence-based guidance. We evaluated the impact of PSA screening, alongside primary care provider utilization, on prostate cancer outcomes for these patients.

Methods: We identified African American men aged 40-55 years, diagnosed with prostate cancer between 2004 and 2017 within the Veterans Health Administration. Inverse probability of treatment-weighted propensity scores were used in multivariable models to assess PSA screening on PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis. Lead-time adjusted Fine-Gray regression evaluated PSA screening on prostate cancer-specific mortality (PCSM), with noncancer death as competing events. All statistical tests were 2-sided.

Results: The cohort included 4726 patients. Mean age was 51.8 years, with 84-month median follow-up. There were 1057 (22.4%) with no PSA screening prior to diagnosis. Compared with no screening, PSA screening was associated with statistically significantly reduced odds of PSA levels higher than 20 (odds ratio [OR] = 0.56, 95% confidence interval [CI] = 0.49 to 0.63; P < .001), Gleason score of 8 or higher (OR = 0.78, 95% CI = 0.69 to 0.88; P < .001), and metastatic disease at diagnosis (OR = 0.50, 95% CI = 0.39 to 0.64; P < .001), and decreased PCSM (subdistribution hazard ratio = 0.52, 95% CI = 0.36 to 0.76; P < .001). Primary care provider visits displayed similar effects.

Conclusions: Among young African American men diagnosed with prostate cancer, PSA screening was associated with statistically significantly lower risk of PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis and statistically significantly reduced risk of PCSM. However, the retrospective design limits precise estimation of screening effects. Prospective studies are needed to validate these findings.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prevalence of patients presenting with prostate-specific antigen (PSA) > 20, Gleason score ≥ 8, and metastatic disease at diagnosis, stratified by PSA screening status. Two-proportion z tests showed statistically significant difference in proportions for all panel comparisons (P < .001). All statistical tests were 2-sided.
Figure 2.
Figure 2.
Cumulative incidence function (CIF) for prostate cancer–specific mortality (PCSM), stratified by prostate-specific antigen (PSA) screening status. There is a statistically significant difference between survival curves (Gray test, P < .001) for PSA screening cohorts. Shading indicates 95% confidence intervals. All statistical tests were 2-sided.
See this image and copyright information in PMC

References

    1. DeSantis CE, Miller KD, G, Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211-233. doi: 10.3322/caac.21555. - DOI - PubMed
    1. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc. 2004;291(22):2720–2726. doi: 10.1001/jama.291.22.2720. - DOI - PubMed
    1. Advani AS, Atkeson B, Brown CL, et al. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer. 2003;97(6):1499–1506. doi: 10.1002/cncr.11213. - DOI - PubMed
    1. Andriole GL, Crawford ED, Grubb RL, et al. ; for the PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319. doi: 10.1056/nejmoa0810696. - DOI - PMC - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328. doi: 10.1056/nejmoa0810084. - DOI - PubMed

Substances